Clinical Study
Electrophysiological Studies in Patients with Pulmonary Hypertension: A Retrospective Investigation
Table 1
Baseline characteristics.
| | | All patients () | | | (%) |
| | Gender (f/m) | 28/27 (51/49) | | Comorbidities | | | Coronary heart disease | 10 (18.2%) | | Unknown: 4 (7.5%) | | History of MI | 5 (9.1%) | | CABG | 6 (10.9%) | | Arterial hypertension | 37 (67%) | | Diabetes mellitus | 13 (23.6) | | Medication | | | Vitamin K-Antagonist | 40 (72%) | | ASS | 10 (18.2%) | | Beta-blocker | 21 (38.2%) | | ACE inhibitor | 24 (43.6%) | | AT1 blockers | 7 (12.7%) | | Aldosterone antagonist | 24 (43.6%) | | Diuretics | 44 (80%) | | Amiodoaron | 10 (18.2%) | | Calcium channel blocker | 3 (5.5%) | | Digitoxin/Digoxin | 3/2 (5.5/3.6%) | | Cardiac devices | | | Cardiac pacemaker | 3 (5.5%) | | Indication | Bradyarrhythmia absoluta (), sick sinus syndrome (), bradycardia/tachycardia syndrome () | | ICD | 2 (3.6%) | | Indication | Primary prevention |
|
|
MI: myocardial infarction, CABG: coronary artery bypass graft, ACE: angiotensin converting enzyme, AT1: angiotensin 1, and ICD: implantable cardioverter defibrillator.
|
